GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Madrigal Pharmaceuticals Inc (FRA:YDO1) » Definitions » ROE % Adjusted to Book Value

Madrigal Pharmaceuticals (FRA:YDO1) ROE % Adjusted to Book Value : -3.52% (As of Dec. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Madrigal Pharmaceuticals ROE % Adjusted to Book Value?

Madrigal Pharmaceuticals's ROE % for the quarter that ended in Dec. 2024 was -31.95%. Madrigal Pharmaceuticals's PB Ratio for the quarter that ended in Dec. 2024 was 9.07. Madrigal Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -3.52%.


Madrigal Pharmaceuticals ROE % Adjusted to Book Value Historical Data

The historical data trend for Madrigal Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Madrigal Pharmaceuticals ROE % Adjusted to Book Value Chart

Madrigal Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.40 -16.17 -5.78 -11.02 -8.98

Madrigal Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.82 -14.49 -10.07 -8.73 -3.52

Competitive Comparison of Madrigal Pharmaceuticals's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Madrigal Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Madrigal Pharmaceuticals's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Madrigal Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Madrigal Pharmaceuticals's ROE % Adjusted to Book Value falls into.


;
;

Madrigal Pharmaceuticals ROE % Adjusted to Book Value Calculation

Madrigal Pharmaceuticals's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-81.48% / 9.07
=-8.98%

Madrigal Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-31.95% / 9.07
=-3.52%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Madrigal Pharmaceuticals ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Madrigal Pharmaceuticals's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Madrigal Pharmaceuticals Business Description

Traded in Other Exchanges
Address
200 Barr Harbor Drive, Suite 200, Four Tower Bridge, West Conshohocken, PA, USA, 19428
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

Madrigal Pharmaceuticals Headlines

No Headlines